Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Core Insights - Phathom Pharmaceuticals reported significant revenue growth in 2025, with a net revenue of $175.1 million, a 217% increase from 2024 [12][20] - The company anticipates operating profitability beginning in Q3 2026 and aims to achieve cash flow positivity by 2027 [2][13] Financial Performance - Q4 2025 net revenues were $57.6 million, up from $29.7 million in Q4 2024, reflecting a $27.9 million increase [12] - Full year 2025 operating expenses were $312.5 million, a decrease from $324.7 million in 2024, with non-GAAP operating expenses at $283.8 million [11] - The net loss for Q4 2025 was $21.1 million, significantly reduced from $74.5 million in Q4 2024 [12] Business Developments - Phathom's sales force was realigned in Q4 2025, achieving over 95% strength, and new marketing leadership was recruited to enhance engagement with gastroenterologists [7] - More than 1.1 million VOQUEZNA prescriptions have been filled as of February 2026, with a 24% increase in Q4 prescriptions compared to the previous quarter [7] Capital Structure - The company completed a $130 million equity offering in January 2026, enhancing its financial position [8] - A modification of the term debt facility reduced overall debt and extended the maturity date to February 2029, with a remaining principal of $175 million [9] 2026 Financial Guidance - Phathom expects net revenues of $320–$345 million for 2026, with a gross margin of approximately 80% and non-GAAP operating expenses of $235–$250 million [20] - The company will include certain third-party charges in cost of goods sold starting January 1, 2026, affecting revenue classification [15]